Mirikizumab for treating moderately to severely active ulcerative colitis

  • Technology appraisal guidance
  • TA925
  • Published: 
Download guidance (PDF)

2 Information about mirikizumab

Marketing authorisation indication

2.1 Mirikizumab (Omvoh, Eli Lilly) is indicated for: 'the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.'

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for mirikizumab.

Price

2.3 The list price is £2,056.56 (excluding VAT; emc med data browser accessed August 2023) per:

  • 300 mg vial of concentrate for solution for infusion

  • 2 pack of 100 mg per 1 ml solution for injection pre-filled syringes.

    Costs may vary in different settings because of negotiated procurement discounts.

2.4 The company has a commercial arrangement. This makes mirikizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.